Placental Expression of EG-VEGF and Its PROKR1 and PROKR2 Receptors in Preeclampsia Patients.

Study Overview
=================
Brief Summary
-----------------
The pathophysiology of preeclampsia (PE) is thought to be endothelial dysfunction responsible for the maternal signs of de novo hypertension and proteinuria after 20 weeks. Current concepts suggest that the pathophysiology of preeclampsia and intrauterine growth retardation results from an imbalance of angiogenic factors. A new angiogenic factor EG-VEGF (Endocrine Gland- Derived Vascular Endothelial Growth Factor) also known as Prokineticin 1 (PROK1) appears to be emerging in the pathophysiology of PE. EG-VEGF is a circulating factor which belongs to the family of prokinetics. Dr Alfaidy's MAB2 team at the Cancer and Infections Biology Laboratory (U1292 Biosanté INSERM / UGA / CEA, CEA Grenoble) demonstrated its key role in the control of key processes in placental development and provided evidence through the development of an animal model of preeclampsia. EG -VEGF is directly involved in the development of Pre-Eclampsia. Few studies have evaluated the expression of EG-VEGF in the human placenta.

Official Title
-----------------
Placental Expression of EG-VEGF and Its PROKR1 and PROKR2 Receptors in Preeclampsia Patients.

Conditions
-----------------
Preeclampsia

Intervention / Treatment
-----------------
* Biological: Placenta pathological examination


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients who have given birth by cesarean section at the maternity University Hospital Saint Etienne and all underwent a placenta pathological examination at the Saint Etienne University Hospital. For the pre-eclampsia group: patient with a diagnosis of pre-eclampsia For the control group: patient who had a normal pregnancy Exclusion Criteria: Patient who gave birth naturally Underage patients or under guardianship Patients who do not speak or read French Childbirth under X

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| preeclampsia group<br>25 patients with a diagnostic of preeclampsia, having undergone a placental pathological examination and having given birth by cesarean section. A cross-referencing of data with programme for medicalization of information systems (PMSI) will be realized. Placenta pathological examination will be performed. | Biological: Placenta pathological examination<br>* a placenta pathological examination will be analyzed to examine quantification of EG-VEGF, PROKR1 and PROKR2 receptors.<br>|
| control group<br>10 patients who had a normal pregnancy, having undergone a placental pathological examination and having given birth by cesarean section. A cross-referencing of data with PMSI will be realized. Placenta pathological examination will be performed. | Biological: Placenta pathological examination<br>* a placenta pathological examination will be analyzed to examine quantification of EG-VEGF, PROKR1 and PROKR2 receptors.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Immuno-localization of EG-VEGF staining (ImageJ®) by immunohistochemistry | Measured by placenta pathological examination (immunohistochemistry technical). | At delivery | 
| Quantification of EG-VEGF staining (ImageJ®) by immunohistochemistry | Measured by placenta pathological examination (immunohistochemistry technical). | At delivery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Immuno-localization of the staining of PROKR1 (ImageJ®) by immunohistochemistry | Measured by placenta pathological examination (immunohistochemistry technical). | At delivery | 
| Quantification of the staining of PROKR1 (ImageJ®) by immunohistochemistry | Measured by placenta pathological examination (immunohistochemistry technical). | At delivery | 
| Immuno-localization of the staining of PROKR2 (ImageJ®) by immunohistochemistry | Measured by placenta pathological examination (immunohistochemistry technical). | At delivery | 
| Quantification of the staining of PROKR2 (ImageJ®) by immunohistochemistry Measure by placenta pathological examination (immunohistochemistry technical). | Measured by placenta pathological examination (immunohistochemistry technical). | At delivery | 
| Presence of at least one chronic maternal pathologies describe below | diabetes, hypertension, kidney disease, Systemic Lupus Erythematosus (SLE), antiphospholipid syndrome | At delivery | 
| Obstetric history | Pre-Eclampsia (PE) and intra uterine growth retardation (IUGR), term of onset and severity of Pre-Eclampsia (PE) | At delivery | 
| Presence of an anticoagulant treatment | treatment by aspirin or Heparin or low molecular weight heparins (LMWH) | At delivery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Preeclampsia, EG-VEGF, Prokineticin, cesarean, placenta pathological examination, pregnancy, PROK1 receptor, PROKR2 receptor